Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Wasted Anti-Cancer Agents Due to Cancellations after Dispensing].
Fukuda M, Honda T, Uchida T, Nose S, Kodama Y, Hashizume J, Tsuchiya A, Matsuo K, Kamada M, Honda K, Ishii K, Yamaguchi H, Mukae H, Ashizawa K. Fukuda M, et al. Gan To Kagaku Ryoho. 2022 Aug;49(8):861-865. Gan To Kagaku Ryoho. 2022. PMID: 36046971 Japanese.
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H, Soda H, Nakamura Y, Takasu M, Tomonaga N, Nakano H, Doi S, Nakatomi K, Nagashima S, Takatani H, Fukuda M, Hayashi T, Tsukamoto K, Kohno S. Yamaguchi H, et al. Among authors: fukuda m. Cancer Chemother Pharmacol. 2011 Feb;67(2):331-8. doi: 10.1007/s00280-010-1325-x. Epub 2010 Apr 17. Cancer Chemother Pharmacol. 2011. PMID: 20401612 Clinical Trial.
Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.
Fukuda M, Nakamura Y, Kinoshita A, Soejima Y, Yamaguchi H, Ikeda T, Izumikawa K, Takatani H, Fukuda M, Soda H, Hayashi N, Tsukamoto K, Oka M, Kohno S. Fukuda M, et al. Cancer Chemother Pharmacol. 2012 Nov;70(5):645-51. doi: 10.1007/s00280-012-1952-5. Epub 2012 Aug 22. Cancer Chemother Pharmacol. 2012. PMID: 23010852 Clinical Trial.
A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Ikeda T, Fukuda M, Nakamura Y, Kinoshita A, Senju H, Nakano H, Kitazaki T, Ogawara D, Taniguchi H, Motoshima K, Yamaguchi H, Nakatomi K, Shimada M, Nagashima S, Tsukamoto K, Kohno S; Nagasaki Thoracic Oncology Group. Ikeda T, et al. Among authors: fukuda m. Cancer Chemother Pharmacol. 2014 Sep;74(3):497-502. doi: 10.1007/s00280-014-2527-4. Epub 2014 Jul 18. Cancer Chemother Pharmacol. 2014. PMID: 25034978 Free article. Clinical Trial.
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K, Takemoto S, Ogawara D, Senju H, Sugasaki N, Ikeda T, Yamaguchi H, Nakatomi K, Fukuda M, Izumikawa K, Mukae H. Mizoguchi K, et al. Among authors: fukuda m. Cancer Chemother Pharmacol. 2016 Aug;78(2):377-82. doi: 10.1007/s00280-016-3097-4. Epub 2016 Jun 23. Cancer Chemother Pharmacol. 2016. PMID: 27339148 Clinical Trial.
4,233 results